ArticleFrontiers in immunology2023

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.

Linfeng Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.